Type 1 diabetes mellitus following SARS-CoV-2 mRNA vaccination.

Abstract

PURPOSE:

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines have been reported to trigger immune side effects. Type 1 diabetes as a manifestation of autoimmune/inflammatory syndrome induced by adjuvants has been reported in a limited number of cases after vaccinations. A few type 1 diabetes cases after SARS-CoV-2 vaccination have been reported. This study aims to report type 1 diabetes cases associated with the mRNA-based SARS-CoV-2 vaccination.

METHODS:

We report four cases of type 1 diabetes mellitus after mRNA-based SARS-CoV-2 vaccine, BNT162b2 (Pfizer-BioNTech). In the medical history, one subject had autoimmune thyroid disease. All patients had autoantibodies against glutamate decarboxylase.

RESULTS:

In the presented case series, type 1 diabetes developed a few weeks after BNT162b2 vaccination. After developing type 1 diabetes, the insulin dose requirements of all patients decreased rapidly, and the need for insulin therapy in three patients disappeared during follow-up. Acute deterioration of glucose regulation in a patient followed by BNT162b2 administration may be due to vaccine-induced autoimmune diabetes.

CONCLUSION:

Vaccination with BNT162b2 may trigger type 1 diabetes.

• Authors: Berna İmge Aydoğan, Uğur Ünlütürk, Mustafa Cesur
• Journal: Endocrine (Endocrine) Vol. 78 Issue 1 Pg. 42-46 (10 2022) ISSN: 1559-0100 [Electronic] United States
• PMID: 35809159 (Publication Type: Journal Article)
• Copyright: © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Chemical References

• COVID-19 Vaccines
• Insulins
• RNA, Messenger
• BNT162 Vaccine

Topics

• BNT162 Vaccine
• COVID-19 (prevention & control)
• COVID-19 Vaccines (adverse effects)
• Diabetes Mellitus, Type 1 (etiology)
• Humans
• Insulins
• RNA, Messenger
• SARS-CoV-2
• Vaccination (adverse effects)